| Nov 18 |
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
|
| Nov 15 |
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
|
| Nov 14 |
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
|
| Nov 8 |
Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Skye Bioscience GAAP EPS of -$0.10 beats by $0.15
|
| Nov 7 |
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
|
| Nov 6 |
Skye Bioscience Q3 2024 Earnings Preview
|
| Nov 4 |
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
|
| Nov 1 |
Skye Bioscience to Announce Third Quarter 2024 Results
|
| Oct 29 |
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
|
